デフォルト表紙
市場調査レポート
商品コード
1435589

TNFアルファ阻害剤の世界市場レポート 2024

TNF Alpha Inhibitors Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.96円
TNFアルファ阻害剤の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

TNFアルファ阻害剤の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には2.2%の年間複合成長率(CAGR)で475億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、精密なドラッグデリバリー、患者中心の焦点、免疫療法の進化、市場拡大戦略、および個別化医療アプローチに関連しています。この期間中に予想される主な動向には、現実世界の証拠の利用、併用療法の採用、市場参入戦略、治療用途の拡大、バイオシミラーにおける競合の激化などが含まれます。

TNFアルファ阻害剤市場の成長は、炎症性腸疾患や乾癬などの炎症性疾患の有病率の増加によって推進されています。 TNFアルファ阻害剤は、消化器科、皮膚科、リウマチ科でさまざまな免疫介在性の炎症状態を治療するために広く使用されています。世界の炎症性腸疾患(IBD)の有病率は、潰瘍性大腸炎が10万人年あたり0.5~24.5人、クローン病が10万人年あたり0.1~16人の範囲となっています。全体的なIBD有病率は、年間100,000人あたり396人です。その結果、炎症性疾患の発生率の上昇はTNFアルファ阻害剤の需要の増大に寄与し、市場の拡大を促進します。

TNFアルファ阻害剤市場は、高齢者人口の増加により成長が見込まれています。 65歳以上の高齢者は自己免疫疾患や炎症活動の亢進を起こしやすいため、この層の炎症やアテローム性動脈硬化の軽減にはTNF-α阻害剤が効果的です。たとえば、世界保健機関は、60歳以上の人口は2020年の10億人に対し、2021年10月までに14億人になると予測しています。世界の60歳以上の人口は、2050年までに倍増して21億人になると予想されています。 80歳以上の人口は3倍の4億2,600万人に達します。したがって、高齢者人口の拡大は、TNFアルファ阻害剤市場の重要な推進力となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のTNFアルファ阻害剤市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • レミケード(インフリキシマブ)
  • エンブレル(エタネルセプト)
  • ヒュミラ(アダリムマブ)
  • シムジア(セルトリズマブペゴル)
  • シンポニ(ゴリムマブ)
  • 世界のTNFアルファ阻害剤市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 皮下
  • 静脈内
  • その他
  • 世界のTNFアルファ阻害剤市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 炎症性腸疾患
  • 乾癬性関節炎
  • 潰瘍性大腸炎(UC)
  • 関節リウマチ
  • 強直性脊椎炎
  • その他

第7章 地域および国の分析

  • 世界のTNFアルファ阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のTNFアルファ阻害剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • TNFアルファ阻害剤市場の競合情勢
  • TNFアルファ阻害剤市場の企業プロファイル
    • HanAll Biopharma Co.Ltd.
    • Pfizer Inc.
    • Johnson &Johnson
    • Janssen Biotech lnc.
    • Merck &co. Inc.

第31章 その他の大手および革新的な企業

  • AbbVie Inc.
  • Novartis International AG
  • Sanofi SA
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Amgen Inc.
  • Celgene Corporation
  • LEO Pharma A/S
  • Biogen Inc.
  • Sandoz International GmbH
  • Cadila Healthcare Limited
  • Bionovis SA
  • UCB SA
  • Intas Pharmaceuticals Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r15297

TNF alpha inhibitors are medications used to address inflammatory conditions such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis, aiming to diminish or eliminate inflammation. However, the use of TNF inhibitors may elevate the risk of skin cancer, particularly non-melanoma skin cancers such as squamous cell carcinoma.

The primary drugs in the TNF alpha inhibitors market include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golimumab). Remicade is prescribed for individuals with moderately to severely active Crohn's disease who have not responded to alternative treatments. These medications can be administered through various routes, including oral, subcutaneous, intravenous, among others, and are used to treat a range of conditions such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and more.

The TNF alpha inhibitors market research report is one of a series of new reports from The Business Research Company that provides TNF alpha inhibitors market statistics, including global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tnf alpha inhibitors market size has grown marginally in recent years. It will grow from $43.09 billion in 2023 to $43.57 billion in 2024 at a compound annual growth rate (CAGR) of 1.1%. The expansion witnessed in the historical period can be ascribed to the integration of healthcare systems, the adoption of physicians and prescriptions, increasing patient demand and awareness, advancements in biotechnology, and the broadening of indications.

The tnf alpha inhibitors market size is expected to see steady growth in the next few years. It will grow to $47.54 billion in 2028 at a compound annual growth rate (CAGR) of 2.2%. The anticipated growth in the forecast period is linked to precision drug delivery, a patient-centric focus, the evolution of immunotherapy, market expansion strategies, and a personalized medicine approach. Key trends expected during this period encompass the utilization of real-world evidence, the adoption of combination therapies, market entry strategies, the broadening of therapeutic applications, and increased competition in biosimilars.

The growth of the TNF alpha inhibitor market is driven by the increasing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis. TNF alpha inhibitors find widespread use in gastroenterology, dermatology, and rheumatology for treating various immune-mediated inflammatory conditions. Globally, the prevalence of inflammatory bowel disease (IBD) ranges from 0.5-24.5 cases of ulcerative colitis per 100,000 person-years and 0.1-16 cases of Crohn's disease per 100,000 person-years. The overall IBD prevalence stands at 396 cases per 100,000 people annually. Consequently, the rising incidence of inflammatory diseases contributes to a growing demand for TNF alpha inhibitors, fostering market expansion.

The TNF alpha inhibitor market is expected to witness growth due to an increasing geriatric population. The elderly, aged 65 and above, are more prone to autoimmune disorders and heightened inflammatory activity, making TNF-alpha inhibitors effective in reducing inflammation and atherosclerosis in this demographic. For instance, the World Health Organization projected that by October 2021, there would be 1.4 billion people aged 60 and above, compared to 1 billion in 2020. The global population aged 60 or older is anticipated to double to 2.1 billion by 2050, with the number of individuals aged 80 or older tripling to reach 426 million. Hence, the expanding geriatric population is a significant driver for the TNF alpha inhibitors market.

The growth of the TNF alpha inhibitor market is expected to face limitations due to the adverse side effects experienced by patients. Clinical trials and post-marketing surveillance have identified multiple adverse effects of TNF alpha inhibition, including injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. Food and Drug Administration (FDA), TNF alpha inhibitors can lead to severe infections in individuals with compromised immune systems, making them susceptible to bacterial, mycobacterial, fungal, or viral infections. Such infections may manifest as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. Consequently, the presence of these side effects prompts patients to seek alternatives such as non-TNF biologics, thereby impeding the growth of the TNF alpha inhibitors market.

Companies in the TNF alpha inhibitor market are directing their efforts towards research and development. This focus on R&D enables market players to assess and embrace high-quality research proposals from global sources, aiming to deliver biologically and clinically superior performance that ensures a more comfortable patient experience and faster recovery times. A case in point is MyMD Pharmaceuticals, Inc., a US-based clinical stage pharmaceutical company dedicated to extending healthy lifespans. In February 2022, the company disclosed Phase 1 clinical trial data indicating MYMD-1's capacity to reduce tumor necrosis factor-alpha (TNF-a), the molecules considered the root cause of aging, in the blood of healthy human subjects. MYMD-1 has demonstrated efficacy in pre-clinical studies by regulating the immune system as a selective inhibitor of TNF-a, a driver of chronic inflammation.

Major players in the TNF alpha inhibitor market are also actively engaging in strategic collaborations to expand their product portfolios and make TNF-blockers more widely accessible to patients. Product distribution, in this context, involves dispersing products such as TNF-alpha inhibitors throughout the market for purchase. For instance, in June 2023, Mark Cuban Cost Plus Drug Company, a US-based pharmaceutical company, collaborated with Coherus BioSciences Inc., a US-based biopharmaceutical company. The partnership aimed to provide Mark Cuban Cost Plus Drug Company customers with YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA (adalimumab injection), a TNF blocker approved for various conditions. This collaboration is part of Coherus' biosimilar strategy, leveraging its manufacturing and supply chain management capabilities to produce safe and efficient biosimilars with a dependable supply.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics PLC for $27.8 billion. This acquisition aligns with Amgen's core business objective of offering groundbreaking medications that significantly improve the lives of patients with critical diseases. Horizon Therapeutics PLC, a US-based biopharmaceutical company, is involved in developing and marketing TNF inhibitors for treating rheumatoid arthritis (RA).

Major companies operating in the tnf alpha inhibitors market report are HanAll Biopharma Co.Ltd., Pfizer Inc., Johnson & Johnson, Janssen Biotech lnc., Merck & co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Amgen Inc., Celgene Corporation, LEO Pharma A/S, Biogen Inc., Sandoz International GmbH, Cadila Healthcare Limited, Bionovis SA, UCB S.A, Intas Pharmaceuticals Ltd., Samsung Bioepis Co.Ltd., Celltrion Healthcare Co. Ltd., LG Life Sciences Ltd., MedImmune LLC, AryoGen Pharmed Co.Ltd., Ablynx NV, Reliance Life Sciences Pvt. Ltd., CASI Pharmaceuticals Inc., Momenta Pharmaceuticals lnc., EPIRUS Biopharmaceuticals lnc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Gilead Sciences Inc., Ipsen S.A., Kyowa Kirin Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Regeneron Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Hospira Inc., Apotex Inc.

North America was the largest region in the TNF alpha inhibitors market in 2023. The regions covered in the tnf alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tnf alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

TNF Alpha Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tnf alpha inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tnf alpha inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tnf alpha inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug: Remicade (Infliximab); Enbrel (Etanercept); Humira (Adalimumab); Cimzia (Certolizumab Pegol); Simponi (Golimumab)
  • 2) By Route Of Administration: Oral; Subcutaneous; Intravenous; Other Route Of Administration
  • 3) By Disease Type: Inflammatory Bowel Disease; Psoriatic Arthritis; Ulcerative Colitis (UC); Rheumatoid Arthritis; Ankylosing Spondylitis; Other Disease Types
  • Companies Mentioned: HanAll Biopharma Co.Ltd.; Pfizer Inc.; Johnson & Johnson; Janssen Biotech lnc.; Merck & co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. TNF Alpha Inhibitors Market Characteristics

3. TNF Alpha Inhibitors Market Trends And Strategies

4. TNF Alpha Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global TNF Alpha Inhibitors Market Size and Growth

  • 5.1. Global TNF Alpha Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global TNF Alpha Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global TNF Alpha Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. TNF Alpha Inhibitors Market Segmentation

  • 6.1. Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Remicade (Infliximab)
  • Enbrel (Etanercept)
  • Humira (Adalimumab)
  • Cimzia (Certolizumab Pegol)
  • Simponi (Golimumab)
  • 6.2. Global TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Subcutaneous
  • Intravenous
  • Other Route Of Administration
  • 6.3. Global TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Inflammatory Bowel Disease
  • Psoriatic Arthritis
  • Ulcerative Colitis (UC)
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Other Disease Types

7. TNF Alpha Inhibitors Market Regional And Country Analysis

  • 7.1. Global TNF Alpha Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global TNF Alpha Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific TNF Alpha Inhibitors Market

  • 8.1. Asia-Pacific TNF Alpha Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China TNF Alpha Inhibitors Market

  • 9.1. China TNF Alpha Inhibitors Market Overview
  • 9.2. China TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India TNF Alpha Inhibitors Market

  • 10.1. India TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan TNF Alpha Inhibitors Market

  • 11.1. Japan TNF Alpha Inhibitors Market Overview
  • 11.2. Japan TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia TNF Alpha Inhibitors Market

  • 12.1. Australia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia TNF Alpha Inhibitors Market

  • 13.1. Indonesia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea TNF Alpha Inhibitors Market

  • 14.1. South Korea TNF Alpha Inhibitors Market Overview
  • 14.2. South Korea TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe TNF Alpha Inhibitors Market

  • 15.1. Western Europe TNF Alpha Inhibitors Market Overview
  • 15.2. Western Europe TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK TNF Alpha Inhibitors Market

  • 16.1. UK TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany TNF Alpha Inhibitors Market

  • 17.1. Germany TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France TNF Alpha Inhibitors Market

  • 18.1. France TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy TNF Alpha Inhibitors Market

  • 19.1. Italy TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain TNF Alpha Inhibitors Market

  • 20.1. Spain TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe TNF Alpha Inhibitors Market

  • 21.1. Eastern Europe TNF Alpha Inhibitors Market Overview
  • 21.2. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia TNF Alpha Inhibitors Market

  • 22.1. Russia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America TNF Alpha Inhibitors Market

  • 23.1. North America TNF Alpha Inhibitors Market Overview
  • 23.2. North America TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA TNF Alpha Inhibitors Market

  • 24.1. USA TNF Alpha Inhibitors Market Overview
  • 24.2. USA TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada TNF Alpha Inhibitors Market

  • 25.1. Canada TNF Alpha Inhibitors Market Overview
  • 25.2. Canada TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America TNF Alpha Inhibitors Market

  • 26.1. South America TNF Alpha Inhibitors Market Overview
  • 26.2. South America TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil TNF Alpha Inhibitors Market

  • 27.1. Brazil TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East TNF Alpha Inhibitors Market

  • 28.1. Middle East TNF Alpha Inhibitors Market Overview
  • 28.2. Middle East TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa TNF Alpha Inhibitors Market

  • 29.1. Africa TNF Alpha Inhibitors Market Overview
  • 29.2. Africa TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa TNF Alpha Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. TNF Alpha Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. TNF Alpha Inhibitors Market Competitive Landscape
  • 30.2. TNF Alpha Inhibitors Market Company Profiles
    • 30.2.1. HanAll Biopharma Co.Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Janssen Biotech lnc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. TNF Alpha Inhibitors Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Novartis International AG
  • 31.3. Sanofi SA
  • 31.4. AstraZeneca plc
  • 31.5. GlaxoSmithKline plc
  • 31.6. Boehringer Ingelheim International GmbH
  • 31.7. Amgen Inc.
  • 31.8. Celgene Corporation
  • 31.9. LEO Pharma A/S
  • 31.10. Biogen Inc.
  • 31.11. Sandoz International GmbH
  • 31.12. Cadila Healthcare Limited
  • 31.13. Bionovis SA
  • 31.14. UCB S.A
  • 31.15. Intas Pharmaceuticals Ltd.

32. Global TNF Alpha Inhibitors Market Competitive Benchmarking

33. Global TNF Alpha Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The TNF Alpha Inhibitors Market

35. TNF Alpha Inhibitors Market Future Outlook and Potential Analysis

  • 35.1 TNF Alpha Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 TNF Alpha Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 TNF Alpha Inhibitors Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer